| 摘要 |
A composition comprising a compound capable of inhibiting expression of c-Fos(cellular proto-oncogene) and NFATc1(Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1) genes associated with osteoclast differentiation and promoting activity of Runx-2(Runt-related transcription factor 2) gene associated with osteoblast differentiation is provided to reduce side effects, and prevent and treat osseous metabolic disease. A composition for preventing and treating osseous metabolic disease selected from osteoporosis, bone metastatic lesion, primary bone cancer, rheumatoid or degenerative arthritis, periodontal disease, inflammatory alveolar bone absorption disease, inflammatory bone absorption disease and Paget's disease comprises a pharmaceutically effective amount of compound represented by the formula(1) or a pharmaceutically acceptable salt thereof.
|
